Pharmaceutical - vorapaxar


Current filters:


Popular Filters

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review


US drug giant Merck & Co says it has started a rolling submission to the US Food and Drug Administration…

Cardio-vascularMerck & CoMK-3475North AmericaOncologyPharmaceuticalRegulationUSAvorapaxarZontivity

Merck & Co's NDA for vorapaxar accepted for standard review by US FDA


US pharma giant Merck & Co (NYSE: MRK) has said the New Drug Application (NDA) for its once-troubled…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationvorapaxar

Merck & Co to file for approval of two heart drugs next year


US drugs giant Merck & Co (NYSE: MRK) says that, following a review of the clinical trial data and discussions…

anacetrapibCardio-vascularEuropeMerck & CoNorth AmericaPharmaceuticalRegulationResearchTredaptivevorapaxar

Study shows vorapaxar reduces cardiovascular events, but raises bleeding worries


Confirming earlier mixed top-line results, US drug giant Merck & Co (NYSE: MRK; The Pharma Letter February…

Cardio-vascularMerck & CoPharmaceuticalResearchvorapaxar

Merck & Co vorapaxar meets goals, but raises bleeding problem


US drug giant Merck & Co (NYSE: MRK) yesterday announced the top-line results of the TRA-2P (Thrombin…

Cardio-vascularMerck & CoPharmaceuticalResearchvorapaxar

Back to top